{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:01:30Z","timestamp":1783526490893,"version":"3.55.0"},"reference-count":22,"publisher":"Georg Thieme Verlag KG","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1055\/a-2057-1840","type":"journal-article","created":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T22:48:53Z","timestamp":1722638933000},"page":"948-954","source":"Crossref","is-referenced-by-count":2,"title":["Chronische Hepatitis-B- und Hepatitis-D-Virusinfektion"],"prefix":"10.1055","volume":"149","author":[{"given":"Giuseppe","family":"Rusignuolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Thimme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Neumann-Haefelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,8,2]]},"reference":[{"key":"ref1","first-page":"3","article-title":"Anstieg der \u00fcbermittelten Hepatitis-B-und Hepatitis-C-F\u00e4lle in Deutschland im Jahr 2022","volume":"31","author":"R Biallas","year":"2023","journal-title":"Epid Bull"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.jhep.2020.04.008","article-title":"The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis","volume":"73","author":"AJ Stockdale","year":"2020","journal-title":"J Hepatol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","author":"European Association for the Study of the Liver (EASL)","year":"2017","journal-title":"J Hepatol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1055\/a-1498-2512","article-title":"S3-Leitlinie der Deutschen Gesellschaft fur Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion (AWMF-Register-Nr. 021\u201311)","volume":"59","author":"M Cornberg","year":"2021","journal-title":"Z Gastroenterol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1053\/j.gastro.2021.11.002","article-title":"Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: an international, multicenter, multiethnic cohort (RETRACT-B Study)","volume":"162","author":"G Hirode","year":"2022","journal-title":"Gastroenterology"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.jhep.2022.01.007","article-title":"Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels","volume":"76","author":"MJ Sonneveld","year":"2022","journal-title":"J Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.jhep.2022.03.006","article-title":"A case of HBV-induced liver failure in the REEF-2 phase II trial: Implications for finite treatment strategies in HBV 'cure'","volume":"77","author":"K Agarwal","year":"2022","journal-title":"J Hepatol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.cgh.2023.08.003","article-title":"Hepatocellular Carcinoma Surveillance Patterns and Outcomes in Patients With Cirrhosis","volume":"22","author":"D Daher","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/s11377-021-00567-7","article-title":"HCC-Surveillance bei Patienten mit chronischer Virushepatitis","volume":"16","author":"C Neumann-Haefelin","year":"2021","journal-title":"Gastroenterologe"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1056\/NEJMra2212151","article-title":"Hepatitis D virus infection","volume":"389","author":"T Asselah","year":"2023","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.1111\/liv.15410","article-title":"Interferon-based treatment of chronic hepatitis D","volume":"43","author":"L Sandmann","year":"2023","journal-title":"Liver Int"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"100686","DOI":"10.1016\/j.jhepr.2023.100686","article-title":"Treating hepatitis D with bulevirtide \u2013 Real-world experience from 114 patients","volume":"5","author":"C Dietz-Fricke","year":"2023","journal-title":"JHEP Rep"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/S0168-8278(23)00522-6","article-title":"Efficacy and safety at 96 weeks of bulevirtide 2 mg or 10 mg monotherapy for chronic hepatitis D: results from an interim analysis of a phase 3 randomized study","volume":"78","author":"H Wedemeyer","year":"2023","journal-title":"J Hepatol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa2213429","article-title":"A phase 3, randomized trial of bulevirtide in chronic hepatitis D","volume":"389","author":"H Wedemeyer","year":"2023","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.jhep.2022.12.023","article-title":"A 3-year course of bulevirtide monotherapy may cure HDV infection in cirrhotics","volume":"78","author":"MP Anolli","year":"2023","journal-title":"J Hepatol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/S0168-8278(23)00594-9","article-title":"Off-label bulevirtide monotherapy for chronic hepatitis D virus infection in patients with decompensated liver disease","volume":"78","author":"C Dietz-Fricke","year":"2023","journal-title":"J Hepatol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jhep.2023.05.001","article-title":"EASL Clinical Practice Guidelines on hepatitis delta virus","volume":"79","author":"European Association for the Study of the Liver (EASL)","year":"2023","journal-title":"J Hepatol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1111\/jvh.13811","article-title":"Bulevirtide-based treatment strategies for chronic hepatitis delta: A review","volume":"30","author":"E Degasperi","year":"2023","journal-title":"J Viral Hepat"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"E81","DOI":"10.1016\/S0618-8278(19)30141-0","article-title":"Final results of a multicenter, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of myrcludex B in combination with PEG-interferon alpha 2a in patients with chronic HBV\/HDV co-infection","volume":"70","author":"H Wedemeyer","year":"2019","journal-title":"J Hepatol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1111\/jvh.13789","article-title":"Beyond bulevirtide: Alternative therapeutic options for the management of hepatitis delta virus","volume":"30","author":"T Asselah","year":"2023","journal-title":"J Viral Hepat"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/liv.15417","article-title":"Emerging anti-HDV drugs and HBV cure strategies with anti-HDV activity","volume":"43","author":"AA Roca Suarez","year":"2023","journal-title":"Liver Int"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"e0084","DOI":"10.1097\/HC9.0000000000000084","article-title":"What will it take to cure hepatitis B?","volume":"7","author":"WJ Jeng","year":"2023","journal-title":"Hepatol Commun"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2057-1840.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T13:10:29Z","timestamp":1730812229000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2057-1840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":22,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2024,8,2]]},"published-print":{"date-parts":[[2024,8]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2057-1840","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8]]}}}